1. Home
  2. PAVM vs RNTX Comparison

PAVM vs RNTX Comparison

Compare PAVM & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PAVmed Inc.

PAVM

PAVmed Inc.

HOLD

Current Price

$6.42

Market Cap

52.1M

Sector

Health Care

ML Signal

HOLD

RNTX

Rein Therapeutics Inc.

HOLD

Current Price

$1.13

Market Cap

47.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PAVM
RNTX
Founded
2014
2001
Country
United States
United States
Employees
41
10
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
52.1M
47.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
PAVM
RNTX
Price
$6.42
$1.13
Analyst Decision
Strong Buy
Buy
Analyst Count
1
2
Target Price
$65.00
$10.00
AVG Volume (30 Days)
14.0K
1.1M
Earning Date
05-15-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$603.94
N/A
Revenue Next Year
$33.16
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.21
$1.00
52 Week High
$28.44
$2.22

Technical Indicators

Market Signals
Indicator
PAVM
RNTX
Relative Strength Index (RSI) 31.54 41.09
Support Level $6.11 $1.09
Resistance Level $10.98 $1.30
Average True Range (ATR) 0.43 0.12
MACD -0.18 -0.03
Stochastic Oscillator 11.93 22.65

Price Performance

Historical Comparison
PAVM
RNTX

About PAVM PAVmed Inc.

PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, EsoCheck, and the Veris Cancer Care Platform.

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.

Share on Social Networks: